Koo...seems to me Brazil and India would be 2 excellent candidates. India has a concentrated wealth that is growing and they also have a huge problem with the growth in diabetes. Brazil has investors looking for big opportunities.

I do believe that the science is not going to drive the share price at all... witness the reaction to the peer reviewed journal article in Atherosclerosis...nothing...but it will take time to sink in.

There are two things that strike me at this stage;

1. Don's Zenith presentation given recently in the USA/SF would not even pass a first year business class presentation. On the business side it was completely open ended. Investors would simply say "Come see us in four years when you have your act together". If the RVX presentations are of the same standard then they should just not bother presenting, unfortunately.
2. Now on the Zenith side if the 12 person proof of concept trial of ZEN-3694 on metastatic cancer shows strong evidence of efficacy then it is a game changer because it even lends more credibility to the RVX side with BETonMACE... IMO.
3. However, on the business side of things, if their corporate development VP...Ken Lebioda is hot on the trail of new regional licensing, and this could happen (Hepalink is a reality), then we very well could see the demand for RVX shares rise dramatically (and price increases as well). I am betting on this because the types of companies that will invest will be paying attention to the growing body of scientifically accepted evidence about apabetalone(rvx-208) as published in the peer reviewed journal Atherosclerosis.

So for me I sense regional deals may be the the key driver for 2016, 2017 and 2018 and it will be supported by growing evidence and understanding on the scientific side. Let's not forget that RVX holds patents on apabetalone(rvx-208) and apabetalone + Crestor (rosuvastatin) through 2029 in many countries including the USA. (good luck AZ)

Let's also not forget that RVX is well financed and when $ get tight the money will flow in. BETonMACE will be completed. I sure would like to hear where Hepalink is in regards to the trial in China. I'm concerned that there has been no reporting there and it is well know that the Chinese are big on theft of intellectual property but I'm sure Don's legal begals have this covered.

I remain long (but frustrated) because I believe we have a blockbuster.

So this week we got the wonderful news that Resverlogix achieved publication in an important scientific journal ...Atheroscelosis...and with, as is well known, very positive findings. This presented a huge communications opportunity for press releases online, in the Globe ROB and health section, in the Star, in the Sun, in the New York Times but from what I saw there was nothing!

IMHO there is something missing.

I guess as a final point I think it would be fair to "guess" that RVX would be bought out quickly but the only issue is price and this gives me consolation because I believe that Don, Dr Wong, Eastern, NGN and Hepalink know what they have and the price will be huge. With the inclusion of Hepalink with 13% ownership and a seat on the board as I and others have posted it may be the linchpin and BP will never get it. A nice bit of leverage indeed.

GLTA

Toinv